Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report.

Drug Safety - Case Reports Pub Date : 2018-05-21 DOI:10.1007/s40800-018-0086-z

Jitendra H Vaghela, Vivek Nimbark, Manish Barvaliya, Hita Mehta, Bhavesh Chavada

{"title":"Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report.","authors":"Jitendra H Vaghela, Vivek Nimbark, Manish Barvaliya, Hita Mehta, Bhavesh Chavada","doi":"10.1007/s40800-018-0086-z","DOIUrl":null,"url":null,"abstract":"Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox® (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient developed FDE after taking the third dose of tablet Forecox® for pulmonary tuberculosis. Tablet Forecox® was withdrawn and the patient recovered from the reaction after 15 days of treatment for FDE. As per World Health Organization-Uppsala Monitoring Centre (WHO-UMC) and Naranjo causality assessment criteria, the association between the reaction and tablet Forecox® was possible and probable, respectively. The reaction was moderately (Level 4b) severe according to the Modified Hartwig and Siegel scale. As there is an increased risk of allergic reaction in patients with a history of drug allergy, FDCs should not be used in order to avoid complexity in identifying the culprit drug.","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40800-018-0086-z","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Safety - Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40800-018-0086-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox^® (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient developed FDE after taking the third dose of tablet Forecox^® for pulmonary tuberculosis. Tablet Forecox^® was withdrawn and the patient recovered from the reaction after 15 days of treatment for FDE. As per World Health Organization-Uppsala Monitoring Centre (WHO-UMC) and Naranjo causality assessment criteria, the association between the reaction and tablet Forecox^® was possible and probable, respectively. The reaction was moderately (Level 4b) severe according to the Modified Hartwig and Siegel scale. As there is an increased risk of allergic reaction in patients with a history of drug allergy, FDCs should not be used in order to avoid complexity in identifying the culprit drug.

Abstract Image

查看原文本刊更多论文

抗结核药物致固定药疹1例。

固定药疹(FDE)是一例40岁男性有药物过敏史的患者，由抗结核药物Forecox®片(利福平[利福平]225 mg +异烟肼150 mg +吡嗪酰胺750 mg +乙胺丁醇400 mg)固定剂量联合用药所致。患者在服用第三剂福考克斯®片治疗肺结核后出现FDE。停用Forecox®片剂，患者在治疗FDE 15天后从反应中恢复。根据世界卫生组织乌普萨拉监测中心(WHO-UMC)和纳兰霍因果关系评估标准，该反应与福考克斯片剂之间分别存在可能和可能的关联。根据改良Hartwig and Siegel量表，反应为中度(4b级)重度。由于有药物过敏史的患者发生过敏反应的风险增加，因此不应使用fdc，以避免识别罪魁祸首药物的复杂性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Safety - Case Reports

自引率

0.00%

发文量

文献相关原料

公司名称	产品信息	采购帮参考价格